标题
Safety of current treatment options for NTRK fusion-positive cancers
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-17
出版商
Informa UK Limited
发表日期
2023-10-23
DOI
10.1080/14740338.2023.2274426
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- GLP-1 agonist Liraglutide prevents MK‑801–induced schizophrenia‑like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice
- (2023) Meltem Donmez Kutlu et al. BEHAVIOURAL BRAIN RESEARCH
- Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors
- (2023) Yoichi Naito et al. International Journal of Clinical Oncology
- Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.
- (2023) Theodore Willis Laetsch et al. JOURNAL OF CLINICAL ONCOLOGY
- 44O Comparison of clinical outcomes of patients with infantile fibrosarcoma (IFS) treated with larotrectinib in the SCOUT study versus historical cohort: The EPI-VITRAKVI study
- (2023) D. Orbach et al. ESMO Open
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
- (2022) George D. Demetri et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
- (2022) Steven G Waguespack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG)
- (2022) Ami V Desai et al. NEURO-ONCOLOGY
- The promise of TRK inhibitors in pediatric cancers with NTRK fusions
- (2022) Emily R. Blauel et al. Cancer Genetics
- NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
- (2022) Fangfang Liu et al. Frontiers in Oncology
- Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
- (2022) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
- (2022) Maciej Jerzy Krzakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
- (2022) Leo Mascarenhas et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review
- (2022) Christine Martineau et al. SUPPORTIVE CARE IN CANCER
- Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
- (2021) Shivaani Kummar et al. CURRENT PROBLEMS IN CANCER
- Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment
- (2021) Weijie Chen et al. World Journal of Surgical Oncology
- 536P Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
- (2021) T.W. Laetsch et al. ANNALS OF ONCOLOGY
- Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.
- (2021) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.
- (2021) Sébastien Perreault et al. JOURNAL OF CLINICAL ONCOLOGY
- First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.
- (2021) Vincent Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
- (2021) C. B. Westphalen et al. npj Precision Oncology
- Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
- (2021) François Doz et al. NEURO-ONCOLOGY
- NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
- (2020) Alessandro Gambella et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
- (2020) T. Yoshino et al. ANNALS OF ONCOLOGY
- Characterization of On-Target Adverse Events Caused by TRK Inhibitor Therapy
- (2020) D. Liu et al. ANNALS OF ONCOLOGY
- A phase II study of larotrectinib for children with newly diagnosed solid tumors and relapsed acute leukemias harboring TRK fusions: Children’s Oncology Group study ADVL1823.
- (2020) Theodore Willis Laetsch et al. JOURNAL OF CLINICAL ONCOLOGY
- TRK inhibitors: managing on-target toxicities
- (2020) J.S.J. Lim et al. ANNALS OF ONCOLOGY
- Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers
- (2020) Maria Carter-Febres et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS
- (2020) Giles Robinson et al. NEURO-ONCOLOGY
- Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study
- (2019) D S Hong et al. ANNALS OF ONCOLOGY
- TRK Inhibitors: Clinical Development of Larotrectinib
- (2019) Munveer S. Bhangoo et al. Current Oncology Reports
- A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
- (2019) Chia-Chi Lin et al. BRITISH JOURNAL OF CANCER
- Casting More Light on Pediatric Fractures
- (2019) Laura K. Bachrach PEDIATRICS
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
- (2019) A Amatu et al. ANNALS OF ONCOLOGY
- No pain, no gain? The effects of pain-promoting neuropeptides and neurotrophins on fracture healing
- (2019) Seungyup Sun et al. BONE
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma
- (2018) Hadeel Halalsheh et al. PEDIATRIC BLOOD & CANCER
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review
- (2018) Loay Kassem et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3 –Positive Acute Myeloid Leukemia
- (2017) Kristen M. Smith et al. MOLECULAR CANCER THERAPEUTICS
- Infantile NTRK-associated Mesenchymal Tumors
- (2017) Jessica L Davis et al. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
- Targeting TRK family proteins in cancer
- (2017) Yekaterina B. Khotskaya et al. PHARMACOLOGY & THERAPEUTICS
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- NTRKfusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
- (2016) Manju L. Prasad et al. CANCER
- Preclinical characterization and antitumor efficacy of DS-6051b, a novel, orally available small molecule tyrosine kinase inhibitor of ROS1 and NTRKs
- (2016) M. Kiga et al. EUROPEAN JOURNAL OF CANCER
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement
- (2016) Dina El Demellawy et al. PATHOLOGY
- Abstract A146: Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase
- (2016) Stephen Mok et al. Cancer Immunology Research
- Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update
- (2015) Howard A. Burris et al. CANCER RESEARCH
- Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib
- (2015) Victor Wong et al. JNCI-Journal of the National Cancer Institute
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib
- (2015) Victor Wong et al. JNCI-Journal of the National Cancer Institute
- BDNF and its TrkB receptor in human fracture healing
- (2014) Olaf Kilian et al. ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER
- Mechanisms of neuroblastoma regression
- (2014) Garrett M. Brodeur et al. Nature Reviews Clinical Oncology
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer
- (2013) Justin F. Gainor et al. Journal of Thoracic Oncology
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight
- (2013) Brittany L. Mason et al. Obesity
- Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study
- (2011) Jane E. Minturn et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers
- (2010) Joseph R. Ghilardi et al. BONE
- The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors
- (2008) Stephen Skaper CNS & Neurological Disorders-Drug Targets
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started